Display options
Cite
Kuusanmäki H, Dufva O, Parri E, et al. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget. 2017;8(57):97516-97527doi: 10.18632/oncotarget.22178.
Kuusanmäki, H., Dufva, O., Parri, E., van Adrichem, A. J., Rajala, H., Majumder, M. M., Yadav, B., Parsons, A., Chan, W. C., Wennerberg, K., Mustjoki, S., & Heckman, C. A. (2017). Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 8(57), 97516-97527. https://doi.org/10.18632/oncotarget.22178
Kuusanmäki, Heikki, et al. "Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling." Oncotarget vol. 8,57 (2017): 97516-97527. doi: https://doi.org/10.18632/oncotarget.22178
Kuusanmäki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K, Mustjoki S, Heckman CA. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget. 2017 Oct 31;8(57):97516-97527. doi: 10.18632/oncotarget.22178. eCollection 2017 Nov 14. PMID: 29228628; PMCID: PMC5722580.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Oct 31;8(57):97516-97527. doi: 10.18632/oncotarget.22178. eCollection 2017 Nov 14.

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Oncotarget

Heikki Kuusanmäki, Olli Dufva, Elina Parri, Arjan J van Adrichem, Hanna Rajala, Muntasir M Majumder, Bhagwan Yadav, Alun Parsons, Wing C Chan, Krister Wennerberg, Satu Mustjoki, Caroline A Heckman

Affiliations

  1. Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  2. Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  3. Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
  4. Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.

PMID: 29228628 PMCID: PMC5722580 DOI: 10.18632/oncotarget.22178

Abstract

Constitutive JAK/STAT3 signaling contributes to disease progression in many lymphoproliferative disorders. Recent genetic analyses have revealed gain-of-function

Keywords: Hsp90 and JAK inhibitors; STAT3 mutation; hematological malignancy; high-throughput compound screening

Conflict of interest statement

CONFLICTS OF INTEREST SM has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb and research funding from Ariad (unrelated to this project). CAH has received resear

References

  1. Int J Lab Hematol. 2010 Aug 1;32(4):419-26 - PubMed
  2. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7 - PubMed
  3. Blood. 2001 Feb 1;97(3):708-13 - PubMed
  4. Ann N Y Acad Sci. 2006 Dec;1091:151-69 - PubMed
  5. N Engl J Med. 2010 Sep 16;363(12):1117-27 - PubMed
  6. J Immunol. 1985 Mar;134(3):1623-30 - PubMed
  7. Haematologica. 2014 Jul;99(7):e105-7 - PubMed
  8. Curr Biol. 2000 Jan 13;10(1):47-50 - PubMed
  9. Leukemia. 2016 Nov;30(11):2245-2247 - PubMed
  10. J Exp Med. 2011 Jul 4;208(7):1359-66 - PubMed
  11. JAKSTAT. 2013 Apr 1;2(2):e23828 - PubMed
  12. Immunity. 1999 Jan;10(1):105-15 - PubMed
  13. Sci Rep. 2014 Jun 05;4:5193 - PubMed
  14. Cancer Discov. 2013 Dec;3(12):1416-29 - PubMed
  15. Proc Natl Acad Sci U S A. 1995 Sep 12;92 (19):8705-9 - PubMed
  16. Nat Commun. 2015 Jan 14;6:6025 - PubMed
  17. Biochem Biophys Res Commun. 2003 Jan 24;300(4):847-52 - PubMed
  18. N Engl J Med. 2012 May 17;366(20):1905-13 - PubMed
  19. Cancers (Basel). 2014 Apr 16;6(2):897-925 - PubMed
  20. Leukemia. 2013 Nov;27(11):2244-7 - PubMed
  21. Cell. 1995 Jul 28;82(2):241-50 - PubMed
  22. Leukemia. 2013 Jul;27(7):1598-600 - PubMed
  23. J Hematol Oncol. 2011 Aug 01;4(1):31 - PubMed
  24. Cancer Cell. 2012 Nov 13;22(5):645-55 - PubMed
  25. Eur J Biochem. 1999 Jul;263(2):438-46 - PubMed
  26. Blood Cancer J. 2016 Feb 26;6:e397 - PubMed
  27. Nat Genet. 2015 Nov;47(11):1304-15 - PubMed
  28. J Clin Invest. 2010 Oct;120(10):3578-93 - PubMed
  29. Blood. 2012 Oct 11;120(15):3048-57 - PubMed
  30. Blood Cancer J. 2013 Nov 29;3:e166 - PubMed
  31. Chem Biol. 2006 Nov;13(11):1235-42 - PubMed
  32. Leukemia. 2016 May;30(5):1204-8 - PubMed
  33. J Clin Invest. 2001 Feb;107(3):351-62 - PubMed
  34. J Leukoc Biol. 1996 Oct;60(4):441-52 - PubMed
  35. Leukemia. 2015 Dec;29(12):2427-9 - PubMed
  36. Blood. 1998 Aug 15;92(4):1374-83 - PubMed
  37. PLoS One. 2015 Jul 01;10(7):e0130078 - PubMed
  38. Neoplasia. 2010 Jan;12(1):39-50 - PubMed
  39. Cancer Cell. 2015 Apr 13;27(4):516-32 - PubMed
  40. EMBO J. 1995 Mar 15;14(6):1166-75 - PubMed
  41. Cell Commun Signal. 2009 Jul 16;7:17 - PubMed
  42. N Engl J Med. 2012 Aug 9;367(6):495-507 - PubMed
  43. Bioinformatics. 2017 Aug 1;33(15):2413-2415 - PubMed
  44. Oncogene. 2015 Mar 12;34(11):1341-53 - PubMed

Publication Types